Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

This study has been completed.
Information provided by (Responsible Party):
Seattle Genetics, Inc. Identifier:
First received: October 24, 2011
Last updated: May 20, 2015
Last verified: May 2015
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: December 2014
  Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
No publications provided by Seattle Genetics, Inc.

Publications automatically indexed to this study by Identifier (NCT Number):